SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models

Sarah A. Bird; Marco P. Licciardello; Salomon Morales; Mara Mandelia; Enze Liu; Yakinthi Chrisochoidou; Amy Wilson; Jack Cheung; Shannon Martin; Yigen Li; Fernando J. Sialana; Brian A. Walker; Paul A. Clarke; Charlotte Pawlyn

doi:10.1038/s41408-026-01632-6

Enriched recordOpen access

SETD2 is a novel and druggable dependency in IMiD/CELMoD resistant multiple myeloma models

Sarah A. Bird, Marco P. Licciardello, Salomon Morales, Mara Mandelia, Enze Liu, Yakinthi Chrisochoidou, Amy Wilson, Jack Cheung, Shannon Martin, Yigen Li, Fernando J. Sialana, Brian A. Walker, Paul A. Clarke, Charlotte Pawlyn

Blood Cancer Journal2026doi:10.1038/s41408-026-01632-6

Citation graph

Abstract

No public abstract is available from the verified source records.

Authors

Sarah A. Bird#1 Marco P. Licciardello#2 Salomon Morales#3 Mara Mandelia#4 Enze Liu#5 Yakinthi Chrisochoidou#6 Amy Wilson#8 Jack Cheung#9 Shannon Martin#10 Yigen Li#11

Referenced works

View all references →

IMiD/CELMoD resistance in myeloma is associated with changes in lipid metabolism that may be targetable

2026 · 0 citations

Cited by

View all cited-by records →

No local citing links have been materialized yet.

External reference records

10.1182/blood-2021-151147

10.1182/blood-2021-151147 · 2021

10.1007/s00018-022-04352-9

10.1007/s00018-022-04352-9 · 2022

10.1038/bcj.2012.37

10.1038/bcj.2012.37 · 2012

10.1182/blood-2018-99-110803

10.1182/blood-2018-99-110803 · 2018

10.1016/j.bneo.2026.100281

10.1186/s13059-021-02540-7

10.1186/s13059-021-02540-7 · 2021

10.1158/1541-7786.mcr-21-0828

10.1158/1541-7786.mcr-21-0828 · 2022

10.18632/oncotarget.28350

10.18632/oncotarget.28350 · 2023

Additional external references

No additional external references are available.